Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer

What are the current treatment patterns and attrition rates in metastatic castration-resistant prostate cancer (mCRPC)?In this cohort study of 5096 patients with mCRPC initiating first-line treatment between January 2021 and June 2025, 54% received second-line treatment and 26% received third-line treatment. Androgen receptor pathway inhibitors were the most common treatments in first and second lines, while taxanes became the most used option in later lines of treatment.These findings suggest that there is a need for optimized sequencing strategies, more efficacious frontline therapies, and interventions to improve access to treatment for mCRPC.

Corresponding Authors: Umang Swami, MD, MSCI (umang.swami@hci.utah.edu), and Neeraj Agarwal, MD (neeraj.agarwal@hci.utah.edu), Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Ste 5510, Salt Lake City, UT 84112.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.